Skip to Content

Nanoviricides Inc NNVC

Morningstar Rating
$1.10 −0.08 (6.38%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

NNVC is trading at a 65% discount.
Price
$1.18
Fair Value
$1.26
Uncertainty
Extreme
1-Star Price
$63.76
5-Star Price
$1.73
Economic Moat
Txr
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NNVC is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.18
Day Range
$1.091.19
52-Week Range
$1.002.00
Bid/Ask
$1.08 / $1.44
Market Cap
$12.96 Mil
Volume/Avg
22,510 / 30,551

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
7

Valuation

Metric
NNVC
Price/Earnings (Normalized)
Price/Book Value
1.11
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
NNVC
Quick Ratio
5.52
Current Ratio
5.59
Interest Coverage
−194.82
Quick Ratio
NNVC

Profitability

Metric
NNVC
Return on Assets (Normalized)
−53.92%
Return on Equity (Normalized)
−58.21%
Return on Invested Capital (Normalized)
−59.29%
Return on Assets
NNVC
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRWpwdpqvhcdSjfk$550.4 Bil
VRTX
Vertex Pharmaceuticals IncHmgdlyhDlhjwb$101.7 Bil
REGN
Regeneron Pharmaceuticals IncQxvhtpqlhPltpq$98.1 Bil
MRNA
Moderna IncGlhbtbcMwcp$38.8 Bil
ARGX
argenx SE ADRGmdxznxjGctww$21.7 Bil
BNTX
BioNTech SE ADRBzrdzxbMdy$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncWzdyybbkYfddcp$18.4 Bil
BMRN
Biomarin Pharmaceutical IncVphyzjklvKbyjly$17.1 Bil
RPRX
Royalty Pharma PLC Class AHrpbfygjTlrdjg$12.5 Bil
INCY
Incyte CorpKzmhkrgymNjdwmv$11.9 Bil

Sponsor Center